Effect of Melatonin Supplementation on Glycemic and Lipid Profiles in Kidney Transplant Recipients: A Clinical Trial
DOI:
https://doi.org/10.61882/ijkd.20.4.9579Keywords:
Melatonin, Kidney transplantation, Diabetes mellitus, Blood glucose, Randomized controlled trialAbstract
Introduction. Melatonin plays a crucial role in regulating sleep and has potent antioxidant properties. However, the relationship between melatonin supplementation and metabolic factors related to diabetes and lipid profiles—which are associated with increased mortality in kidney transplant recipients has not yet been fully clarified.
Methods. This randomized, double-blind, placebo-controlled trial was conducted at Labbafinejad Hospital, Tehran, Iran. Adult kidney transplant recipients (≥6 months post-transplant) received either 6 mg/day melatonin or placebo for three months. A modified intention-to-treat analysis included 42 patients per group. The primary outcomes were changes in fasting blood sugar (FBS) and HbA1c levels, while secondary outcomes included blood pressure and lipid profile parameters. Between-group effects were estimated using linear regression adjusted for baseline values and confounders. Results. In the melatonin group, FBS decreased by a median of 6.5 mg/dL (P < .001) and HbA1c by 0.25 units (P < .001), whereas both parameters increased in the placebo group. The adjusted between-group effect favored melatonin for HbA1c (β = −0.30%; 95% CI: −0.59 to −0.01; P < .001) but not for FBS (β = −2.61 mg/dL; 95% CI: −17.93 to 12.71; P = .283). Triglyceride levels decreased by 16 mg/dL in the melatonin group compared with an increase of 13.5 mg/dL in the placebo group (adjusted β = −23.77 mg/dL; 95% CI: −45.50 to −2.04; P = .032). No significant differences were observed in blood pressure and renal function.
Conclusion. Melatonin supplementation for three months modestly improved glycemic control and lowered serum triglyceride levels in kidney transplant recipients, with no effects on blood pressure or kidney function. These results support melatonin’s potential as an adjunct therapy for metabolic dysregulation in this population, warranting further investigation into its long-term benefits.
Downloads
References
1. Liu X, Shen J, Yan H, et al. Posttransplant complications: molecular mechanisms and therapeutic interventions. MedComm. 2024;5(9):e669. DOI: 10.1002/mco2.669
2. Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. 2019;15(3):172-88. DOI: 10.1038/s41574-
018- 0137-7
3. Agarwal A, Prasad GV. Post-transplant dyslipidemia: Mechanisms, diagnosis and management. World J Transplant. 2016;6(1):125-34. DOI: 10.5500/wjt.v6.i1.125
4. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57(1):307-13. DOI: 10.1046/j.1523-1755.2000.00816.x
5. Esteban-Zubero E, García-Gil FA, López-Pingarrón L, et al. Potential benefits of melatonin in organ transplantation: a review. J Endocrinol. 2016;229(3):R129-R46. DOI: 10.1530/JOE-16-0117
6. Bondeva T, Wolf G. Reactive oxygen species in diabetic nephropathy: friend or foe? Nephrol Dial Transplant. 2014;29(11):1998-2003. DOI: 10.1093/ndt/gfu037
7. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008;4(5):285-93. DOI: 10.1038/ncpendmet0786
8. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review
on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59(7):365-73. DOI: 10.1016/j.biopha.2005.07.002
9. Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61(3):253-78. DOI: 10.1111/jpi.12360
10. Rubio-Sastre P, Scheer FA, Gómez-Abellán P, Madrid JA, Garaulet M. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep. 2014;37(10):1715-9. DOI: 10.5665/sleep.4088
11. Gil-Lozano M, Hunter PM, Behan LA, Gladanac B, Casper RF, Brubaker PL. Short-term sleep deprivation with nocturnal light exposure alters time-dependent glucagon-like peptide-1 and insulin secretion in male volunteers. Am J Physiol Endocrinol Metab. 2016;310(1):E41-50. DOI: 10.1152/ajpendo.00298.2015
12. Xia Q, Chen ZX, Wang YC, et al. Association between the melatonin receptor 1B gene polymorphism on the risk of type 2 diabetes, impaired glucose regulation: a meta-analysis. PloS one. 2012;7(11):e50107. DOI: 10.1371/journal.pone.0050107
13. Garaulet M, Qian J, Florez JC, Arendt J, Saxena R, Scheer F. Melatonin Effects on Glucose Metabolism: Time To Unlock the Controversy. Trends Endocrinol Metab. 2020;31(3):192-204. DOI: 10.1016/j.tem.2019.11.011
14. Canteras NS, Ribeiro-Barbosa ER, Goto M, Cipolla-Neto J, Swanson LW. The retinohypothalamic tract: comparison of axonal projection patterns from four major targets. Brain Res Rev. 2011;65(2):150-83. DOI: 10.1016/j. brainresrev.2010.09.006
15. la Fleur SE, Kalsbeek A, Wortel J, van der Vliet J,
Buijs RM. Role for the pineal and melatonin in glucose homeostasis: pinealectomy increases night-time glucose concentrations. J Neuroendocrinol. 2001;13(12):1025-32. DOI: 10.1046/j.1365-2826.2001.00717.x
16. Markus RP, Sousa KS, da Silveira Cruz-Machado S, Fernandes PA, Ferreira ZS. Possible Role of Pineal
and Extra-Pineal Melatonin in Surveillance, Immunity, and First-Line Defense. Int J Mol Sci. 2021;22(22). DOI: 10.3390/ijms222212143
17. Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014;19(9):1410-8. DOI: 10.1016/j. drudis.2014.04.014
18. Picinato MC, Hirata AE, Cipolla-Neto J, et al. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets.
J Pineal Res. 2008;44(1):88-94. DOI: 10.1111/j.1600-079X.2007.00493.x
19. Rahman A, Hasan AU, Kobori H. Melatonin in chronic kidney disease: a promising chronotherapy targeting the intrarenal renin–angiotensin system. Hypertens Res. 2019;42(6):920-3. DOI: 10.1038/s41440-019-0223-9
20. Ostadmohammadi V, Soleimani A, Bahmani F, et al. The Effects of Melatonin Supplementation on Parameters
of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. J Ren Nutr. 2020;30(3):242-50. DOI: 10.1053/j.jrn.2019.08.003
21. Theofilis P, Vordoni A, Kalaitzidis RG. The Role of Melatonin in Chronic Kidney Disease and Its Associated Risk Factors: A New Tool in Our Arsenal? Am J Nephrol. 2022;53(7):565-74. DOI: 10.1159/000525441
22. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2009;32(1):193-203. DOI: 10.2337/dc08-9025
23. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes care. 2024;47(Suppl 1):S158-s78. DOI: 10.2337/dc24-er07a
24. Costes S, Boss M, Thomas AP, Matveyenko AV. Activation of Melatonin Signaling Promotes β-Cell Survival and Function. Mol Endocrinol. 2015;29(5):682-92. DOI: 10.1210/me.2014-1293
25. Nath A, Ghosh S, Bandyopadhyay D. Role of melatonin in mitigation of insulin resistance and ensuing diabetic cardiomyopathy. Life Sci. 2024;355:122993. DOI: 10.1016/j.lfs.2024.122993
26. Goyal A, Terry PD, Superak HM, et al. Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial. Diabetol Metab Syndr. 2014;6(1):124. DOI: 10.1186/1758-5996-6-124
27. Drexel H, Tamargo J, Kaski JC, et al. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease? Eur Heart J Cardiovasc Pharmacother. 2023;9(6):570-82. DOI: 10.1093/ehjcvp/pvad044
28. Markowska M, Niemczyk S, Romejko K. Melatonin Treatment in Kidney Diseases. Cells. 2023;12(6). DOI: 10.3390/cells12060838
Downloads
Published
Data Availability Statement
The supporting for this report is available on request from the corresponding author.
